* Announces that its partner Exelixis obtained FDA
approval of CABOMETYX (cabozantinib) tablets for patients with
advanced renal cell carcinoma who have received prior
anti-angiogenic therapy
Source…
The post BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets appeared first on NASDAQ.